Article

Identification of a novel GOPC-RET fusion in a patient with lung adenocarcinoma: A case report

2022-12-13

Abstract excerpt

<h4>Background: </h4> RET fusion has reported in 1–2% of lung adenocarcinomas, and it is one of the key driver mutations and an actionable target. Non-small cell lung cancer (NSCLC) patients harboring RET fusion can obtained clinical benefit from the therapy with multi-kinase inhibitors like cabozantinib and potent and highly selective RET inhibitors like selpercatinib (LOXO-292) and pralsetinib (BLU-667). In NSCL...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aa993475-4dba-52d6-bbdb-043462879669
DOI: 10.21203/rs.3.rs-2359851/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel GOPC-RET fusion in a patient with lung adenocarcinoma: A case reportDOI 10.21203/rs.3.rs-2359851/v1Read

Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencingSemantic proximity Read

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020Semantic proximity Read

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read

The Genomic Characteristics of RET Fusion Positive Tumors in Chinese Non-Small Cell Lung Cancer (NSCLC) PatientsSemantic proximity Read

Clinically relevant fusion oncogenes: detection and practical implicationsSemantic proximity Read

Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.Semantic proximity Read

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusionsSemantic proximity Read

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients.Semantic proximity Read

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.Semantic proximity Read

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subsetSemantic proximity Read

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese populationSemantic proximity Read